Sanofi and MSD’s hexavalent vaccine in USFebruary 5, 2019
US FDA has approved diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine (Vaxelis) for use in children from 6 weeks through 4 years of age.
The combination vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type b. It is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).
Sanofi and MSD are working to maximize production of Vaxelis to allow for a sustainable supply to meet anticipated US demand. Commercial supply will not be available in the U.S. prior to 2020.
The hexavalent vaccine was developed as part of a joint venture established in 1991 between Merck & Co, Inc and Sanofi Pasteur, the vaccines unit of Sanofi